Camilla Soenderby

About Camilla Soenderby

Camilla Soenderby is an international biopharmaceutical executive best known today for her role as an independent board member of Abivax. She brings to the company substantial experience in governance, global product strategy, and commercial execution, built over more than 25 years across leading healthcare organizations in Europe, the United States, and Asia. Her appointment to Abivax in 2024 added senior-level expertise to the board at a pivotal moment for a listed biotechnology company operating in a highly competitive and capital-intensive environment. Before joining Abivax, Soenderby served as corporate officer at Takeda, where she led global portfolio commercialization and commercial excellence, working closely with research and development teams. She previously held the role of Senior Vice President, Head of Global Product Strategy at Shire, a position focused on portfolio strategy, launch readiness, and long-term international growth. Earlier in her career, she held regional and general management roles at Roche Pharma, Abbott — now AbbVie — and Schering-Plough, giving her broad exposure to both mature and fast-growing pharmaceutical businesses. Her expertise is particularly strong in rare diseases, oncology, and specialty therapeutics, with notable experience in inflammatory bowel disease. In that context, she was involved in the strategic development and commercialization of Humira (adalimumab) and Entyvio (vedolizumab), two major products in IBD care. She started her career as a healthcare consultant at McKinsey & Company, a background that likely contributed to her analytical and strategic leadership style. Alongside her Abivax board mandate, she serves on the boards of BB Biotech, F2G, and Affibody, is a member of the Novo Holdings Advisory Group, and acts as an industrial advisor to EQT, reflecting her strong standing in the European life sciences governance landscape.